GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BG Medicine Inc (OTCPK:BGMD) » Definitions » Cash Conversion Cycle

BG Medicine (BG Medicine) Cash Conversion Cycle : -794.45 (As of Dec. 2015)


View and export this data going back to 2011. Start your Free Trial

What is BG Medicine Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

BG Medicine's Days Sales Outstanding for the three months ended in Dec. 2015 was 52.39.
BG Medicine's Days Inventory for the three months ended in Dec. 2015 was 204.76.
BG Medicine's Days Payable for the three months ended in Dec. 2015 was 1051.6.
Therefore, BG Medicine's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2015 was -794.45.


BG Medicine Cash Conversion Cycle Historical Data

The historical data trend for BG Medicine's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BG Medicine Cash Conversion Cycle Chart

BG Medicine Annual Data
Trend Dec05 Dec06 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only -324.81 -145.82 -121.60 -120.63 -214.49

BG Medicine Quarterly Data
Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -50.78 -149.94 -126.59 -572.96 -794.45

Competitive Comparison of BG Medicine's Cash Conversion Cycle

For the Medical Instruments & Supplies subindustry, BG Medicine's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BG Medicine's Cash Conversion Cycle Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BG Medicine's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where BG Medicine's Cash Conversion Cycle falls into.



BG Medicine Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

BG Medicine's Cash Conversion Cycle for the fiscal year that ended in Dec. 2015 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=41.37+196.96-452.82
=-214.49

BG Medicine's Cash Conversion Cycle for the quarter that ended in Dec. 2015 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=52.39+204.76-1051.6
=-794.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BG Medicine  (OTCPK:BGMD) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


BG Medicine Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of BG Medicine's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


BG Medicine (BG Medicine) Business Description

Traded in Other Exchanges
N/A
Address
303 Wyman Street, Suite 300, Waltham, MA, USA, 02451
BG Medicine Inc manufacture and sell diagnostic products that are used to guide the patients suffering from heart failure and related disorders in the United States. It distributes its products such as BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme-linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.
Executives
Jeffrey R Luber director 100 CAMPUS DRIVE, C/O EXACT SCIENCES CORP, MARLBOROUGH MA 01752
Noubar Afeyan director, 10 percent owner C/O FLAGSHIP PIONEERING, INC., 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Stelios Papadopoulos director 3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
Harry W Wilcox director ONE KENDALL SQ, BLDG 700, CAMBRIDGE MA 02139
Agtc Partners, L.p. 10 percent owner C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142
Newcogen Group, Inc. 10 percent owner C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142
Applied Genomic Technology Capital Fund Lp 10 percent owner C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142
Flagship Pioneering Inc. 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Agtc Advisors Fund Lp 10 percent owner ONE MEMORIAL DRIVE 7TH FLOOR CAMBRIDGE MA 02142
Kania Edwin M Jr 10 percent owner
Flagship Ventures Fund 2007, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures 2007 General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Brian S Posner director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Stephane Bancel director 320 BENT STREET, CAMBRIDGE MA 02141
Harris Timothy J.r. director C/O BG MEDICINE, 610 LINCOLN STREET NORTH, WALTHAM MA 02451

BG Medicine (BG Medicine) Headlines

No Headlines